Evidence map›Paper›PMID 35618895›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

CRISPR Library Screening in Cultured Cardiomyocytes.

Sophia DeLuca, Nenad Bursac

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sophia DeLucaDepartment of Cell Biology, Duke University, Durham, NC, USA.
Nenad BursacDepartment of Biomedical Engineering, Duke University, Durham, NC, USA. nenad.bursac@duke.edu.
Duke University · US

Funding

Training Program in Developmental & Stem Cell BiologyT32HD040372 · NICHD · DUKE UNIVERSITY · PI Terry H Lechler · 2001 to 2026
$8.9M
Integrated Cellular and Tissue Engineering for Ischemic Heart DiseaseU01HL134764 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BURSAC, NENAD, KAMP, TIMOTHY J. · 2016 to 2022
$7.7M
University Training Program in Biomolecular and Tissue EngineeringT32GM144291 · NIGMS · DUKE UNIVERSITY · PI Charles A. Gersbach, Tatiana Segura · 2022 to 2026
$2.6M
In Vitro and In Situ Engineering of Fibroblasts for Cardiac RepairR01HL132389 · NHLBI · DUKE UNIVERSITY · PI BURSAC, NENAD · 2016 to 2019
$2.0M
Microphysiological Human Tissue Systems for Monitoring of Genome Editing OutcomesU01HL156348 · NHLBI · DUKE UNIVERSITY · PI BURSAC, NENAD, GERSBACH, CHARLES A. · 2020 to 2022
$2.0M
Microphysiological Human Tissue Systems for Monitoring of Genome Editing OutcomesU01EB028901 · NIBIB · DUKE UNIVERSITY · PI BURSAC, NENAD, GERSBACH, CHARLES A. · 2019 to 2019
$668k
NHLBI NIH HHS R01 HL132389NHLBI NIH HHS U01 HL134764NHLBI NIH HHS U01 HL156348NIBIB NIH HHS U01 EB028901NICHD NIH HHS T32 HD040372NIGMS NIH HHS T32 GM144291
6 · The paper itself

Abstract

CRISPR-Cas9-based screening technologies enable precise, high-throughput genetic and epigenetic manipulation to study mechanisms of development and disease and identify new therapeutic targets. Here, we describe a general protocol for the generation of custom, pooled CRISPR sgRNA libraries for screening in cardiomyocyte cultures. This methodology can address a variety of lab-specific research questions in cardiomyocytes and other cell types, as the genes to be modified can be curated or whole genomes can be investigated. The use of lentiviral sgRNA delivery followed by high-throughput sequencing allows for rapid comparison and identification of candidate genes and epigenetic modifiers, which can be further validated individually or in sub-pooled libraries following screening.

Indexed as

CRISPR-Cas SystemsMyocytes, CardiacGene LibraryGenomeHigh-Throughput Nucleotide SequencingCardiomyocyteCRISPRGenetic screenHigh-throughputKnock-outMaturationProliferationSurvival

Identifiers

PMID35618895
PMCPMC9274507
OpenAlexW4285309275

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.